z-logo
Premium
Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development
Author(s) -
Duns Gerben,
Hofstra Robert M.W.,
Sietzema Jantine G.,
Hollema Harry,
van Duivenbode Inge,
Kuik Angela,
Giezen Cor,
Jan Osinga,
Bergsma Jelkje J.,
Bijnen Harrie,
van der Vlies Pieter,
van den Berg Eva,
Kok Klaas
Publication year - 2012
Publication title -
human mutation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.981
H-Index - 162
eISSN - 1098-1004
pISSN - 1059-7794
DOI - 10.1002/humu.22090
Subject(s) - bap1 , biology , clear cell renal cell carcinoma , exome sequencing , cancer research , chromatin , arid1a , gene , histone , tumor suppressor gene , mutation , genetics , carcinogenesis , renal cell carcinoma , medicine , oncology
Abstract Clear cell renal cell carcinomas are characterized by 3p loss, and by inactivation of Von Hippel Lindau ( VHL ), a tumorsuppressor gene located at 3p25. Recently, SETD2 , located at 3p21, was identified as a new candidate ccRCC tumor‐suppressor gene. The combined mutational frequency in ccRCC tumors of VHL and SETD2 suggests that there are still undiscovered tumor‐suppressor genes on 3p. We screened all genes on 3p for mutations in 10 primary ccRCC tumors using exome‐sequencing. We identified inactivating mutations in VHL , PBRM1 , and BAP1 . Sequencing of PBRM1 in ccRCC‐derived cell lines confirmed its frequent inactivation in ccRCC. PBRM1 encodes for BAF180, the chromatin targeting subunit of the SWI/SNF complex. BAP1 encodes for BRCA1 associated protein‐1, involved in histone deubiquitination. Taken together, the accumulating data suggest an important role for aberrant chromatin regulation in ccRCC development. Hum Mutat 33:1059–1062, 2012. © 2012 Wiley Periodicals, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here